Donor Natural Killer Cell Infusion, Rituximab, Aldesleukin, and Chemotherapy in Treating Patients With Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia

NCT00625729 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

6

Enrollment

OTHER

Sponsor class

Stopped No patients exhibited natural killer cell expansion (primary endpoint).

Conditions

Leukemia
Lymphoma

Interventions

BIOLOGICAL: aldesleukin
BIOLOGICAL: allogeneic natural killer cells
BIOLOGICAL: rituximab
DRUG: cyclophosphamide
DRUG: fludarabine phosphate

Sponsor

Masonic Cancer Center, University of Minnesota

Collaborators

[object Object]